CRISPR-Based Therapy for Hereditary Angioedema

In this randomized, controlled trial, the number of angioedema attacks per month was approximately 75% lower among adults with hereditary angioedema who received a CRISPR-Cas9–based therapy than among those who received placebo.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology